Bioequivalence Study of Netupitant/Palonosetron Oral Suspension Versus Capsules in Healthy Volunteers: An Open-Label, Randomized, Replicative Design

The primary objective of this study is to evaluate the **bioequivalence** of an oral suspension formulation of the netupitant/palonosetron combination product compared to its hard capsule counterpart. This assessment is conducted following a single-dose administration in healthy male and female volunteers. Establishing bioequivalence is clinically relevant as it ensures that the new formulation provides the same therapeutic effect and safety profile as the existing product, which is crucial for maintaining consistent patient outcomes.

The clinical trial involves **healthy volunteers** as the study population, encompassing both male and female participants. The age range of the participants is categorized under code "3," which typically includes adults. The trial does not focus on a vulnerable population. The sponsor has not provided information regarding the total number of participants. The selection criteria for the trial population, as well as any specific lifestyle considerations such as diet or physical activity, have not been disclosed. Key inclusion or exclusion criteria are also not specified by the sponsor.

The clinical trial is designed to evaluate the **bioequivalence** of an oral suspension of a netupitant/palonosetron combination product compared to its hard capsule form. This study will be conducted in an open-label, randomized, single-center, two-treatment, four-period, two-sequence replicative design. The trial will involve healthy male and female volunteers and is categorized as a Phase 2 study. The estimated recruitment start date is January 28, 2024, with an anticipated end date of September 30, 2024.

Participants will undergo a series of study visits, beginning with an inclusion visit, which serves as the screening phase to determine eligibility based on predefined criteria. Following successful screening, participants will be randomized into one of the two treatment sequences. The trial will include multiple follow-up visits to monitor the participants' response to the treatment and to collect necessary data. The end-of-study visit will conclude the trial, where final assessments will be conducted to ensure participant safety and to gather comprehensive data for analysis.

The expected length of participant involvement will span the duration of the trial, from the initial screening to the end-of-study visit. Conditions that may lead to early termination from the study include adverse reactions to the treatment, non-compliance with study protocols, or withdrawal of consent by the participant. The study aims to ensure the safety and well-being of all participants while achieving its research objectives.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the absence of specific details, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be included. The data does not contain any information about the experimental or non-experimental treatments used in the study, and as such, a comprehensive description cannot be formulated.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to begin recruitment on January 28, 2024, with an estimated end date of September 30, 2024. The efficacy assessment will be conducted through a series of planned evaluations, although specific parameters or endpoints for efficacy evaluation are not detailed in the provided data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The study will adhere to rigorous clinical trial standards to ensure the reliability and validity of the efficacy outcomes.